{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:38:54Z","timestamp":1791866334352,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>ZUMA\u20101 (NCT02348216) examined the safety and efficacy of axicabtagene ciloleucel (axi\u2010cel), an autologous CD19\u2010directed chimaeric antigen receptor (CAR)\u2010T cell therapy, in refractory large B\u2010cell lymphoma. To reduce treatment\u2010related toxicity, several exploratory safety management cohorts were added to ZUMA\u20101. Specifically, cohort 6 investigated management of cytokine release syndrome (CRS) and neurologic events (NEs) with prophylactic corticosteroids and earlier corticosteroid and tocilizumab intervention. CRS and NE incidence and severity were primary end\u2010points. Following leukapheresis, patients could receive optional bridging therapy per investigator discretion. All patients received conditioning chemotherapy (days \u22125 through \u22123), 2\u00a0\u00d7\u00a010<jats:sup>6<\/jats:sup>\u00a0CAR\u2010T cells\/kg (day 0) and once\u2010daily oral dexamethasone [10\u00a0mg, day 0 (before axi\u2010cel) through day 2]. Forty patients received axi\u2010cel. CRS occurred in 80% of patients (all grade \u22642). Any grade and grade 3 or higher NEs occurred in 58% and 13% of patients respectively. Sixty\u2010eight per cent of patients did not experience CRS or NEs within 72\u00a0h of axi\u2010cel. With a median follow\u2010up of 8\u00b79\u00a0months, objective and complete response rates were 95% and 80% respectively. Overall, prophylactic corticosteroids and earlier corticosteroid and\/or tocilizumab intervention resulted in no grade 3 or higher CRS, a low rate of grade 3 or higher NEs and high response rates in this study population.<\/jats:p>","DOI":"10.1111\/bjh.17527","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T05:58:56Z","timestamp":1627019936000},"page":"690-700","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":209,"title":["Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B\u2010cell lymphoma"],"prefix":"10.1111","volume":"194","author":[{"given":"Olalekan O.","family":"Oluwole","sequence":"first","affiliation":[{"name":"Vanderbilt\u2010Ingraham Cancer Center Nashville TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krimo","family":"Bouabdallah","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et Th\u00e9rapie Cellulaire CHU Bordeaux Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Banner MD Anderson Cancer Center Gilbert AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"De Guibert","sequence":"additional","affiliation":[{"name":"H\u00f4pital de Pontchaillou Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center Washington University School of Medicine St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Deol","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Center Wayne State University Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"McSweeney","sequence":"additional","affiliation":[{"name":"Colorado Blood Cancer Institute Denver CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre H.","family":"Goy","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center Hackensack University Medical Center Hackensack NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"Amsterdam UMC University of Amsterdam Amsterdam Netherlands on behalf of HOVON\/LLPC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-9891","authenticated-orcid":false,"given":"Umar","family":"Farooq","sequence":"additional","affiliation":[{"name":"University of Iowa Iowa City IA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht Utrecht Netherlands on behalf of HOVON\/LLPC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris AP\u2010HP, H\u00f4pital Saint\u2010Louis Hemato\u2010oncology, DMU HI; Research Unit NF\u2010kappaB Diff\u00e9renciation et Cancer Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Timmerman","sequence":"additional","affiliation":[{"name":"UCLA David Geffen School of Medicine Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Stiff","sequence":"additional","affiliation":[{"name":"Loyola University Chicago Stritch School of Medicine Maywood IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[{"name":"Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tzachanis","sequence":"additional","affiliation":[{"name":"Moores Cancer Center, UCSD La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Bashir","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"McLeroy","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Johnson","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovely","family":"Goyal","sequence":"additional","affiliation":[{"name":"Kite, a Gilead Company Santa Monica CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van Meerten","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen Groningen Netherlands on behalf of HOVON\/PPLC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"YESCARTA\u00ae(axicabtagene ciloleucel) [summary of product characteristics].Amsterdam the Netherlands:Kite Pharma EU B.V.;2018."},{"key":"e_1_2_10_3_1","unstructured":"YESCARTA\u00ae(axicabtagene ciloleucel) Prescribing information. KitePharma Inc;2021."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000191"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2595"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238691"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0582-9"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126081"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_10_16_1","unstructured":"U.S. Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.2010.National Institutes of Health National Cancer Institute."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142932"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003001"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3150"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.025"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S150524"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008865"},{"issue":"1","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-134362","article-title":"Long\u2010term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi\u2010cel)","volume":"136","author":"Jacobson CA","year":"2020","journal-title":"Blood"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002228"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401456"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0280-y"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.12.10"}],"updated-by":[{"DOI":"10.1111\/bjh.20237","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000}}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17527","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T17:35:27Z","timestamp":1692812127000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1111\/bjh.17527"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17527","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"assertion":[{"value":"2020-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}